At SGS proderm, we are committed to enhancing subject panel diversity in clinical trials. We believe that diversity is crucial for improving healthcare and its importance in supporting marketing claims for products intended for different markets should not be overlooked. By conducting clinical trials with diverse subject panels, companies can ensure that their products are safe and effective for a wide range of people, including those from underrepresented populations. This can improve the chances of gaining regulatory approval for the product in different regions and can help to build trust with customers in those markets. At SGS proderm, we understand the importance of subject diversity in supporting marketing claims, and we work closely with our clients to ensure that their clinical trials are designed to meet the diverse needs of their target markets.
But what do we mean by subject panel diversity? When it comes to subject panels in clinical trials, several parameters are considered important for diversity. These include both parameters describing physical traits such as skin / hair type, gender and age. Other factors that may be considered include geographic location, and lifestyle factors. The specific parameters that are considered important for diversity may vary depending on the specific trial and the population that is being studied. But the goal in every instance is to ensure that the subject panel is representative of the population that will be affected by the condition being studied.